Usefulness of Statin Pretreatment to Prevent Contrast-Induced Nephropathy and to Improve Long-Term Outcome in Patients Undergoing Percutaneous Coronary Intervention

American Journal of Cardiology

Volumn 101, Issue 3, 2008, Pages 279-285

  Patti, Giuseppe ^a   Nusca, Annunziata ^a   Chello, Massimo ^a   Pasceri, Vincenzo ^b   D'Ambrosio, Andrea ^a   Vetrovec, George W ^c   Di Sciascio, Germano ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SAN FILIPPO NERI HOSPITAL   (Italy)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SURVIVAL;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CONTRAST MEDIA; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; LENGTH OF STAY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRAVASTATIN; PREOPERATIVE CARE; PYRIMIDINES; PYRROLES; SIMVASTATIN; SULFONAMIDES;

EID: 38549127836     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.08.030     Document Type: Article

References (28)

1. Pasceri V., Patti G., Nusca A., Pristipino C., Richichi G., and Di Sciascio G. A Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention. Results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 110 (2004) 674-678
2. Patti G., Pasceri V., Colonna G., Miglionico M., Fischetti D., Sardella G., Montinaro A., and Di Sciascio G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 49 (2007) 1272-1278
3. Patti G., Chello M., Candura D., Pasceri V., D'Ambrosio A., Covino E., and Di Sciascio G. A randomized trial of atorvastatin for reduction of post-operative atrial fibrillation in patients undergoing cardiac surgery. Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) Study. Circulation 114 (2006) 1455-1461
4. Patti G., Chello M., Pasceri V., Colonna D., Nusca A., Miglionico M., D'Ambrosio A., Covino E., and Di Sciascio G. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention. Results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) Substudy. J Am Coll Cardiol 48 (2006) 1560-1566
5. Goldenberg I., and Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. Can Med Assoc J 172 (2005) 1461-1471
6. Tumlin J., Stacul F., Adam A., Becker C.R., Davidson C., Lameire N., McCullough P.A., and CIN Consensus Working Panel. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 98 suppl (2006) 14K-20K
7. Khanal S., Attallah N., Smith D.E., Kline-Rogers E., Share D., O'Donnell M.J., and Moscucci M. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 118 (2005) 843-849
8. Attallah N., Yassine L., Musial J., Yee J., and Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol 62 (2004) 273-278
9. McCullough P.A. Beyond serum creatinine: defining the patient with renal insufficiency and why?. Rev Cardiovasc Med 4 suppl 1 (2003) S2-S6
10. Cigarroa R.G., Lange R.A., Williams R.H., and Hillis L.D. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 86 (1989) 649-652
11. Saucedo J.F., Mehran R., Dangas G., Hong M.K., Lansky A., Kent K.M., Satler L.F., Pichard A.D., Stone G.W., and Leon M.B. Long term clinical events following creatine kinase-myocardial band isoenzyme elevation after successful coronary stenting. J Am Coll Cardiol 35 (2000) 1134-1141
12. Gibson C.M., Dumaine R.L., Gelfand E.V., Murphy S.A., Morrow D.A., Wiviott S.D., Giugliano R.P., Cannon C.P., Antman E.M., Braunwald E., and TIMI Study Group. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J 25 (2004) 1998-2005
13. Ting H.H., Tahirkheli N.K., Berger P.B., McCarthy J.T., Timimi F.K., Mathew V., Rihal C.S., Hasdai D., and Holmes D.R. Evaluation of long term survival after successful percutaneous coronary intervention among patients with chronic renal failure. Am J Cardiol 87 (2001) 630-633
14. Rihal C.S., Textor S.C., Grill D.E., Berger P.B., Ting H.H., Best P.J., Singh M., Bell M.R., Barsness G.W., Mathew V., Garratt K.N., and Holmes D.R. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105 (2002) 2259-2264
15. Gruberg L., Mintz G.S., Mehran R., Dangas G., Lansky A.J., Kent K.M., Pichard A.D., Satler L.F., and Leon M.B. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 36 (2000) 1542-1548
16. Ichiki T., Takeda K., Tokunou T., Iino N., Egashira K., Shimokawa H., Hirano K., Kanaide H., and Takeshita A. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21 (2001) 1896-1901
17. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., Sanchez-Pascuala R., Hernandez G., Diaz C., and Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101 (1998) 2711-2719
18. Bakris G.L., Lass N., Gaber A.O., Jones J.D., and Burnett Jr. J.C. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 258 suppl (1990) F115-F120
19. Bonetti P.O., Lerman L.O., Napoli C., and Lerman A. Statin effects beyond lipid lowering-are they clinically relevant?. Eur Heart J 24 (2003) 225-248
20. Chello M., Goffredo C., Patti G., Candura D., Melfi R., Mastrobuoni S., Di Sciascio G., and Covino E. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Cardiothorac Surg 28 (2005) 805-810
21. Zapolska-Downar D., Siennicka A., Kaczmarczyk M., Kolodziej B., and Naruszewicz M. Simvastatin modulates TNFalpha-induced adhesion molecules expression in human endothelial cells. Life Sci 75 (2004) 1287-1302
22. Laufs U., Fata V.L., and Liao J.K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 272 (1997) 31725-31729
23. Rikitake Y., Kawashima S., Takeshita S., Yamashita T., Azumi H., Yasuhara M., Nishi H., Inoue N., and Yokoyama M. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154 (2001) 87-96
24. Mason J.C., Ahmed Z., Mankoff R., Lidington E.A., Ahmad S., Bhatia V., Kinderlerer A., Randi A.M., and Haskard D.O. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res 91 (2002) 696-703
25. Lecian D., Demova H., Lodererova A., Zdychova J., Kluckova H., Teplan V., Voska L., and Komers R. Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis. Kidney Blood Press Res 29 (2006) 135-143
26. Dallas H.W. Abnormalities of kidney function as a cause and a consequence of cardiovascular disease. Am J Med Sci 317 (1999) 176-182
27. Guitterez N.V., Diaz A., and Timmis G.C. Determinations of serum creatinine trajectory in acute contrast nephropathy. J Interv Cardiol 15 (2002) 349-354
28. Mehran R., Aymong E.D., Nikolsky E., Lasic Z., Iakovou I., Fahy M., Mintz G.S., Lansky A.J., Moses J.W., Stone G.W., Leon M.B., and Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention. J Am Coll Cardiol 44 (2004) 1393-1399